Although BRAF inhibitors have recently entered clinical use for treating BRAF-mutant cancers, cancers are known to have spatial and temporal heterogeneity, and mutations not identified in primary tumors have been shown to exist in metastatic tumors12,13. The gene discussed is BRAF; the disease is cancer.